Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425262 | 0.86 | KDM4E (0.40) | KCNH2KDM4EMAPTNPSR1HTR2A | |
| SCHEMBL4429968 | 0.79 | NCOA3 (0.48) | KCNH2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL4422196 | 0.76 | PDE10A (0.41) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL4422312 | 0.74 | KDM4E (0.45) | KDM4EMAPTNPSR1HTR2AHTR2C | |
| SCHEMBL4435635 | 0.74 | CYP11B1 (0.48) | KCNH2PIK3CAPIK3CG | |
| SCHEMBL4423160 | 0.74 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL4423505 | 0.71 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL4427072 | 0.71 | KCNH2 (0.53) | KCNH2 | |
| SCHEMBL4425220 | 0.69 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL4433933 | 0.68 | KCNH2 (0.70) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101798298-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2013-01-09 | — | — | CN | disclosed |
| CN-101798298-A | Imdazole derivatives | HOFFMANN LA ROCHE | 2010-08-11 | — | — | CN | disclosed |
| CN-1489580-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| EP-1358165-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| CN-1489580-A | Imidazole derivatives | - | 2004-04-14 | — | — | CN | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | KCNH2 592/4885KDM4E 1141/4885MAPT 101/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | KCNH2 352/4885KDM4E 1192/4885MAPT 448/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | KCNH2 352/4885KDM4E 1192/4885MAPT 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.